Clinical Trials Browser

Sezary Syndrome × mogamulizumab × Lymphoid × Clear all

NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Phase 1/2 Terminated

8 enrolled 8 charts

Mycosis Fungoides, Sezary Syndrome

NCT04930653 2025-10-14

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Phase 2 Recruiting

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT07132567 2025-09-22

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

Mycosis Fungoides, Sezary Syndrome

NCT04256018 2025-07-02

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Phase 2 Recruiting

Mycosis Fungoides, Sezary Syndrome

NCT05455931 2024-09-04

PROSPER

Active not recruiting

Mycosis Fungoides, Sezary Syndrome

NCT04676087 2024-08-13

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

Phase 1/2 Terminated

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Phase 3 Completed

372 enrolled 14 charts 1 FDA

DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT04185220 2023-01-04

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

Phase 1 Completed

6 enrolled 16 charts

LymphoidOther hematologic neoplasm

Mycosis Fungoides, Sezary Syndrome, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma